García-Cañaveras, Juan C. http://orcid.org/0000-0001-7112-1537
Lancho, Olga
Ducker, Gregory S.
Ghergurovich, Jonathan M. http://orcid.org/0000-0002-6565-2275
Xu, Xincheng
da Silva-Diz, Victoria
Minuzzo, Sonia
Indraccolo, Stefano
Kim, Hahn
Herranz, Daniel http://orcid.org/0000-0003-1768-5969
Rabinowitz, Joshua D. http://orcid.org/0000-0002-1247-4727
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R00CA215307, R01CA236936, R00CA197869, 1DP1DK113643, R01CA163591)
New Jersey Commision on Cancer Research
U.S. Department of Health & Human Services | National Institutes of Health
American Cancer Society (RSG-19-161-01-TBE)
Alex's Lemonade Stand Foundation for Childhood Cancer
Leukemia Research Foundation
Gabrielle's Angel Foundation for Cancer Research
U.S. Department of Health & Human Services | National Institutes of Health
Rutgers Cancer Institute of New Jersey (P30CA072720, P30CA072720)
Children’s Leukemia Research Association
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 19 November 2019
Revised: 9 April 2020
Accepted: 22 April 2020
First Online: 7 May 2020
Compliance with ethical standards
:
: GSD, JMG, HK, and JDR are inventors on a Princeton University patent covering serine hydroxymethyltransferase inhibitors and their use in cancer. JDR is a co-founder of Raze Therapeutics and advisor and stock owner in Kadmon, Agios, L.E.A.F., and Rafael Pharmaceuticals. No competing interests were disclosed by the other authors.